Literature DB >> 27084639

Robustness Recipes for Minimax Robust Optimization in Intensity Modulated Proton Therapy for Oropharyngeal Cancer Patients.

Sebastian van der Voort1, Steven van de Water2, Zoltán Perkó3, Ben Heijmen2, Danny Lathouwers3, Mischa Hoogeman4.   

Abstract

PURPOSE: We aimed to derive a "robustness recipe" giving the range robustness (RR) and setup robustness (SR) settings (ie, the error values) that ensure adequate clinical target volume (CTV) coverage in oropharyngeal cancer patients for given gaussian distributions of systematic setup, random setup, and range errors (characterized by standard deviations of Σ, σ, and ρ, respectively) when used in minimax worst-case robust intensity modulated proton therapy (IMPT) optimization. METHODS AND MATERIALS: For the analysis, contoured computed tomography (CT) scans of 9 unilateral and 9 bilateral patients were used. An IMPT plan was considered robust if, for at least 98% of the simulated fractionated treatments, 98% of the CTV received 95% or more of the prescribed dose. For fast assessment of the CTV coverage for given error distributions (ie, different values of Σ, σ, and ρ), polynomial chaos methods were used. Separate recipes were derived for the unilateral and bilateral cases using one patient from each group, and all 18 patients were included in the validation of the recipes.
RESULTS: Treatment plans for bilateral cases are intrinsically more robust than those for unilateral cases. The required RR only depends on the ρ, and SR can be fitted by second-order polynomials in Σ and σ. The formulas for the derived robustness recipes are as follows: Unilateral patients need SR = -0.15Σ(2) + 0.27σ(2) + 1.85Σ - 0.06σ + 1.22 and RR=3% for ρ = 1% and ρ = 2%; bilateral patients need SR = -0.07Σ(2) + 0.19σ(2) + 1.34Σ - 0.07σ + 1.17 and RR=3% and 4% for ρ = 1% and 2%, respectively. For the recipe validation, 2 plans were generated for each of the 18 patients corresponding to Σ = σ = 1.5 mm and ρ = 0% and 2%. Thirty-four plans had adequate CTV coverage in 98% or more of the simulated fractionated treatments; the remaining 2 had adequate coverage in 97.8% and 97.9%.
CONCLUSIONS: Robustness recipes were derived that can be used in minimax robust optimization of IMPT treatment plans to ensure adequate CTV coverage for oropharyngeal cancer patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27084639     DOI: 10.1016/j.ijrobp.2016.02.035

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

Review 1.  Target Definition in MR-Guided Adaptive Radiotherapy for Head and Neck Cancer.

Authors:  Mischa de Ridder; Cornelis P J Raaijmakers; Frank A Pameijer; Remco de Bree; Floris C J Reinders; Patricia A H Doornaert; Chris H J Terhaard; Marielle E P Philippens
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

2.  Dosimetric evaluation of synthetic CT generated with GANs for MRI-only proton therapy treatment planning of brain tumors.

Authors:  Samaneh Kazemifar; Ana M Barragán Montero; Kevin Souris; Sara T Rivas; Robert Timmerman; Yang K Park; Steve Jiang; Xavier Geets; Edmond Sterpin; Amir Owrangi
Journal:  J Appl Clin Med Phys       Date:  2020-03-26       Impact factor: 2.102

3.  Quantification of plan robustness against different uncertainty sources for classical and anatomical robust optimized treatment plans in head and neck cancer proton therapy.

Authors:  Macarena Cubillos-Mesías; Esther G C Troost; Fabian Lohaus; Linda Agolli; Maximilian Rehm; Christian Richter; Kristin Stützer
Journal:  Br J Radiol       Date:  2019-11-28       Impact factor: 3.039

4.  Impact of robust treatment planning on single- and multi-field optimized plans for proton beam therapy of unilateral head and neck target volumes.

Authors:  Macarena Cubillos-Mesías; Michael Baumann; Esther G C Troost; Fabian Lohaus; Steffen Löck; Christian Richter; Kristin Stützer
Journal:  Radiat Oncol       Date:  2017-11-28       Impact factor: 3.481

5.  Worst case optimization for interfractional motion mitigation in carbon ion therapy of pancreatic cancer.

Authors:  Julian Steitz; Patrick Naumann; Silke Ulrich; Matthias F Haefner; Florian Sterzing; Uwe Oelfke; Mark Bangert
Journal:  Radiat Oncol       Date:  2016-10-07       Impact factor: 3.481

6.  Cerebral cortex dose sparing for glioblastoma patients: IMRT versus robust treatment planning.

Authors:  Ann-Katrin Exeli; Daniel Kellner; Lukas Exeli; Phil Steininger; Frank Wolf; Felix Sedlmayer; Heinz Deutschmann
Journal:  Radiat Oncol       Date:  2018-02-06       Impact factor: 3.481

7.  Potential proton and photon dose degradation in advanced head and neck cancer patients by intratherapy changes.

Authors:  Kristin Stützer; Annika Jakobi; Anna Bandurska-Luque; Steffen Barczyk; Carolin Arnsmeyer; Steffen Löck; Christian Richter
Journal:  J Appl Clin Med Phys       Date:  2017-09-18       Impact factor: 2.102

Review 8.  Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer.

Authors:  Agostino Cristaudo; Mitchell Hickman; Charles Fong; Paul Sanghera; Andrew Hartley
Journal:  Medicines (Basel)       Date:  2018-06-27

9.  Assessment of robustness against setup uncertainties using probabilistic scenarios in lung cancer: a comparison of proton with photon therapy.

Authors:  Suliana Teoh; Ben George; Francesca Fiorini; Katherine A Vallis; Frank Van den Heuvel
Journal:  Br J Radiol       Date:  2020-02-04       Impact factor: 3.629

10.  Difference in LET-based biological doses between IMPT optimization techniques: Robust and PTV-based optimizations.

Authors:  Shusuke Hirayama; Taeko Matsuura; Koichi Yasuda; Seishin Takao; Takaaki Fujii; Naoki Miyamoto; Kikuo Umegaki; Shinichi Shimizu
Journal:  J Appl Clin Med Phys       Date:  2020-03-09       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.